InvestorsHub Logo
Followers 51
Posts 1707
Boards Moderated 0
Alias Born 01/13/2014

Re: James salmon post# 32918

Monday, 09/11/2017 4:31:17 PM

Monday, September 11, 2017 4:31:17 PM

Post# of 108192
For the record (to CAB033) I would not say I am "happy" DOC is gone.

But to James point, what DOC wanted to do was risky. DOCs strategy seemed reasonable if one was just looking at the impressive clinical results and potential of the company. But unfortunately I think the massive short position trumped DOCs agenda and forced the BODs hand to go in another direction. If ADXS was at $20 it wouldn't have been as big of an issue to fund the company with some further dilution. At $6 it was no longer acceptable.

This is a prime example of why I believe shorting in Biotech needs to be aggressively addressed by Congress.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADXS News